A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma.

Sant P ChawlaSanjay GoelWarren ChowFadi BraitehArun S SinghJuneko E Grilley OlsonAtsushi OsadaIulian BobeRichard F Riedel

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

NC-6300 was well tolerated with a manageable side effect profile, despite the MTD and RP2D being higher than conventional epirubicin doses. A signal of preliminary activity was observed in angiosarcoma. NC-6300 warrants further investigation in patients with advanced solid tumors, including sarcoma.

Keyphrases

squamous cell carcinoma
small cell lung cancer
clinical trial
study protocol
phase ii
open label
locally advanced
randomized controlled trial
radiation therapy